2025 Q4 -tulosraportti
Vain PDF
17 päivää sitten
Tarjoustasot
Nordic Growth Market
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 544 | SHB | AVA | ||
| 4 456 | SHB | NON | ||
| 2 000 | AVA | AVA | ||
| 1 000 | ENS | NON | ||
| 44 589 | SWB | DDB |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 22.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 28.11.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2025 Q1 -tulosraportti 23.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·7.9.2025Anyone have any insight into this company? Is it unreasonable to believe that they will be profitable in 2026?
·2.12.2025The company is not burning money, so as soon as the results from the In vitro tests come, it will hopefully be a trigger.·18.12.2025As previously announced, a blood bank in Norway has evaluated our transfusion product, Glycosorb® ABO (4 ml), for the preparation of low-titer blood group O platelet concentrate with good results. The results have recently been presented at a national transfusion congress in Norway. Apheresis platelet concentrate of blood group O contains anti-A/B antibodies (blood group-specific antibodies), and can be transfused to recipients of blood group A, B or AB, as long as the concentrate contains a low titer (level) of these anti-A/B antibodies. The method traditionally used to reduce anti-A/B antibodies from blood group O platelet concentrate involves treating the concentrate with centrifugation and diluting it with a buffer solution. The conclusion from the evaluation was that Glycosorb® ABO (4 ml) was more effective at lowering anti-A/B antibodies than the currently used method, resulted in lower activation of platelets, and that the procedure itself was easy to perform with our product. This confirms the experiences from NHS in the UK last year, where it was shown that anti-A/B antibody titers in platelet concentrate can be effectively reduced with Glycosorb® ABO (4ml). Platelet transfusions are primarily used in oncology, surgery, and hematology, where patients have an increased need for platelets to prevent or treat bleeding. It is estimated that approximately 2.4 million units of platelet concentrate are used annually in Europe. Of these, about 1 million units are apheresis platelets (edqm, 2016).
·15.8.2025When will the results from the in vitro tests come in? They have been excellent and the boundaries of what has been possible have been expanded more and more. silent for three months, flip or flop?- ·30.5.2025I have followed the company for over twenty years as I am from the area and now is the time to invest in the company. They have products under testing and if approved, large orders will flow in. At least that is my hope.
·6.8.2025How does the pipeline for new products look like? Should you buy this stock?·6.8.2025Since the company has historically underperformed, I don't think you need to rush into the stock. The positive is if they can maintain cost control. So probably the best risk/reward to buy in if/when they approach profitability. 
·22.1.2025I can accept all the arguments regarding the directed new issue except for the sky-high percentage discount in relation to the current price and the year's price, due to volatility in the share. If you have that view of the price setting, you should refrain from subscribing unless the intention is, as was the case with the previous directed issue, to stay and sell as long as you are in the black. That pushed the price down for 1.5 years. I hope I am wrong and we see more purchases from these investors.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
17 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·7.9.2025Anyone have any insight into this company? Is it unreasonable to believe that they will be profitable in 2026?·2.12.2025The company is not burning money, so as soon as the results from the In vitro tests come, it will hopefully be a trigger.·18.12.2025As previously announced, a blood bank in Norway has evaluated our transfusion product, Glycosorb® ABO (4 ml), for the preparation of low-titer blood group O platelet concentrate with good results. The results have recently been presented at a national transfusion congress in Norway. Apheresis platelet concentrate of blood group O contains anti-A/B antibodies (blood group-specific antibodies), and can be transfused to recipients of blood group A, B or AB, as long as the concentrate contains a low titer (level) of these anti-A/B antibodies. The method traditionally used to reduce anti-A/B antibodies from blood group O platelet concentrate involves treating the concentrate with centrifugation and diluting it with a buffer solution. The conclusion from the evaluation was that Glycosorb® ABO (4 ml) was more effective at lowering anti-A/B antibodies than the currently used method, resulted in lower activation of platelets, and that the procedure itself was easy to perform with our product. This confirms the experiences from NHS in the UK last year, where it was shown that anti-A/B antibody titers in platelet concentrate can be effectively reduced with Glycosorb® ABO (4ml). Platelet transfusions are primarily used in oncology, surgery, and hematology, where patients have an increased need for platelets to prevent or treat bleeding. It is estimated that approximately 2.4 million units of platelet concentrate are used annually in Europe. Of these, about 1 million units are apheresis platelets (edqm, 2016).
- ·15.8.2025When will the results from the in vitro tests come in? They have been excellent and the boundaries of what has been possible have been expanded more and more. silent for three months, flip or flop?
- ·30.5.2025I have followed the company for over twenty years as I am from the area and now is the time to invest in the company. They have products under testing and if approved, large orders will flow in. At least that is my hope.·6.8.2025How does the pipeline for new products look like? Should you buy this stock?·6.8.2025Since the company has historically underperformed, I don't think you need to rush into the stock. The positive is if they can maintain cost control. So probably the best risk/reward to buy in if/when they approach profitability.
- ·22.1.2025I can accept all the arguments regarding the directed new issue except for the sky-high percentage discount in relation to the current price and the year's price, due to volatility in the share. If you have that view of the price setting, you should refrain from subscribing unless the intention is, as was the case with the previous directed issue, to stay and sell as long as you are in the black. That pushed the price down for 1.5 years. I hope I am wrong and we see more purchases from these investors.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nordic Growth Market
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 544 | SHB | AVA | ||
| 4 456 | SHB | NON | ||
| 2 000 | AVA | AVA | ||
| 1 000 | ENS | NON | ||
| 44 589 | SWB | DDB |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 22.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 28.11.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2025 Q1 -tulosraportti 23.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
2025 Q4 -tulosraportti
Vain PDF
17 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 22.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 28.11.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2025 Q1 -tulosraportti 23.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·7.9.2025Anyone have any insight into this company? Is it unreasonable to believe that they will be profitable in 2026?·2.12.2025The company is not burning money, so as soon as the results from the In vitro tests come, it will hopefully be a trigger.·18.12.2025As previously announced, a blood bank in Norway has evaluated our transfusion product, Glycosorb® ABO (4 ml), for the preparation of low-titer blood group O platelet concentrate with good results. The results have recently been presented at a national transfusion congress in Norway. Apheresis platelet concentrate of blood group O contains anti-A/B antibodies (blood group-specific antibodies), and can be transfused to recipients of blood group A, B or AB, as long as the concentrate contains a low titer (level) of these anti-A/B antibodies. The method traditionally used to reduce anti-A/B antibodies from blood group O platelet concentrate involves treating the concentrate with centrifugation and diluting it with a buffer solution. The conclusion from the evaluation was that Glycosorb® ABO (4 ml) was more effective at lowering anti-A/B antibodies than the currently used method, resulted in lower activation of platelets, and that the procedure itself was easy to perform with our product. This confirms the experiences from NHS in the UK last year, where it was shown that anti-A/B antibody titers in platelet concentrate can be effectively reduced with Glycosorb® ABO (4ml). Platelet transfusions are primarily used in oncology, surgery, and hematology, where patients have an increased need for platelets to prevent or treat bleeding. It is estimated that approximately 2.4 million units of platelet concentrate are used annually in Europe. Of these, about 1 million units are apheresis platelets (edqm, 2016).
- ·15.8.2025When will the results from the in vitro tests come in? They have been excellent and the boundaries of what has been possible have been expanded more and more. silent for three months, flip or flop?
- ·30.5.2025I have followed the company for over twenty years as I am from the area and now is the time to invest in the company. They have products under testing and if approved, large orders will flow in. At least that is my hope.·6.8.2025How does the pipeline for new products look like? Should you buy this stock?·6.8.2025Since the company has historically underperformed, I don't think you need to rush into the stock. The positive is if they can maintain cost control. So probably the best risk/reward to buy in if/when they approach profitability.
- ·22.1.2025I can accept all the arguments regarding the directed new issue except for the sky-high percentage discount in relation to the current price and the year's price, due to volatility in the share. If you have that view of the price setting, you should refrain from subscribing unless the intention is, as was the case with the previous directed issue, to stay and sell as long as you are in the black. That pushed the price down for 1.5 years. I hope I am wrong and we see more purchases from these investors.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nordic Growth Market
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 544 | SHB | AVA | ||
| 4 456 | SHB | NON | ||
| 2 000 | AVA | AVA | ||
| 1 000 | ENS | NON | ||
| 44 589 | SWB | DDB |
Välittäjätilasto
Dataa ei löytynyt